CHD1 and prostate neoplasm: Preclinical studies showed that CHD1 loss-induced HR defects sensitize prostate tumors to PARP inhibitors, Olaparib and Talazoparib, both in vitro and in vivo (21, 24, 59, 88), suggesting CHD1 might be a predictive biomarker.